Vor Biopharma Inc. (VOR)
NMS – Real vaqt narxi. Valyuta: USD
16.47
-0.78 (-4.52%)
Yopilishda: May 12, 2026, 4:00 PM EDT
16.47
0.00 (0.00%)
Bozor oldidan: May 13, 2026, 4:30 AM EDT
Find any stock by ticker or company name

NMS – Real vaqt narxi. Valyuta: USD
16.47
-0.78 (-4.52%)
Yopilishda: May 12, 2026, 4:00 PM EDT
16.47
0.00 (0.00%)
Bozor oldidan: May 13, 2026, 4:30 AM EDT
Vor Biopharma Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, autoimmun kasalliklarni davolashda yangi terapiyani ishlab chiqishga qaratilgan. Kompaniya umumiy miyasteniya gravis, tizimli qizil yug'rich va revmatoid artrit, shuningdek, Sjögren kasalligi va IgA nefropatiyasini davolash uchun yangi birikkan oqsil bo'lgan telitaciceptni taklif etadi. U telitacicept va tegishli mahsulotlarni ekspluatatsiya qilish, ishlab chiqish va tijoratlashtirish bo'yicha RemeGen Co., Ltd. bilan litsenziya shartnomasiga ega. Kompaniya 2015 yilda tashkil etilgan va shtab-kvartirasi Boston, Massachusetsda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Jean-Paul Kress M.D. | Chairman, President & CEO |
| Dr. Jeremy Sokolove M.D. | Chief Medical Officer |
| Dr. Navid Z. Khan Ph.D. | Chief Medical Affairs Officer |
| Dr. Robert Ang M.B.A., M.D., MBBS | Strategic Advisor |
| Dr. Siddhartha Mukherjee DPHIL, M.D., Ph.D. | Scientific Founder & Chairman of Scientific Advisory Board |
| Mr. Dallan Murray | Chief Commercial Officer |
| Mr. Sandesh Mahatme L.L.M. | Chief Business Officer & CFO |
| Ms. Adi Osovsky | General Counsel |
| Ms. Carol Lincoln CCP | Head of Human Resources |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-27 | S-3 | d27587ds3.htm |
| 2026-04-27 | DEFA14A | vor-20260422.htm |
| 2026-03-30 | 10-K | vor-20251231.htm |
| 2026-03-27 | 8-K | vor-20260326.htm |
| 2026-02-02 | CORRESP | filename1.htm |
| 2026-01-29 | S-3 | d56846ds3.htm |
| 2026-01-12 | 8-K | vor-20260112.htm |
| 2026-01-02 | 8-K | vor-20251231.htm |
| 2025-12-18 | 8-K | vor-20251215.htm |
| 2025-12-09 | 8-K | vor-20251205.htm |